Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025
The Cambridge Massachusetts-based company is expected to report revenue of $10 million, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of 54 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Seres Therapeutics Inc is $73.70, above its last closing price of $9.63.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -3.75 | -3.94 | -2.00 | Beat | 49.2 |
Sep. 30 2024 | -4.88 | -4.91 | -7.60 | Missed | -54.8 |
Jun. 30 2024 | -5.46 | -5.48 | -4.40 | Beat | 19.7 |
Mar. 31 2024 | -6.95 | -6.82 | -5.40 | Beat | 20.8 |
Dec. 31 2023 | -7.95 | -9.94 | -6.40 | Beat | 35.6 |
Sep. 30 2023 | -9.87 | -10.03 | -7.40 | Beat | 26.2 |
Jun. 30 2023 | 10.58 | 10.68 | 7.20 | Missed | -32.6 |
Mar. 31 2023 | -11.23 | -10.98 | -11.40 | Missed | -3.8 |
This summary was machine generated May 5 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。